Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 44Unknown 19Active not recruiting 6Withdrawn 5Terminated 4Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 99Thoracic 98Gastrointestinal 98Gynecologic 49Genitourinary 30Other solid neoplasm 14Tumor-Agnostic 7CNS 7Endocrine 6Sarcoma 5Breast 5Dermatologic 3Other 2Lymphoid 2Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1NET 1

Conditions

Hodgkin Disease 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 174Rituximab 146venetoclax 82Specimen Handling 81fludarabine 80Vincristine 69obinutuzumab 68Prednisone 66Doxorubicin 66Biopsy 63Magnetic Resonance Spectroscopy 62Lenalidomide 54zanubrutinib 52Dexamethasone 48Cytarabine 44Methotrexate 43blinatumomab 41Immunotherapy, Adoptive 40acalabrutinib 37Bendamustine Hydrochloride 37fludarabine phosphate 32Etoposide 32ibrutinib 30polatuzumab vedotin 27glofitamab 27pirtobrutinib 25orelabrutinib 25Gemcitabine 24Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Cisplatin × Lymphoid × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Canadian Cancer Trials Group

Phase 2 Recruiting
84 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡